- Conditions
- Schizophrenia, Acute Episode
- Interventions
- Elpipodect, Risperidone, Placebo matching MK-8189, Placebo matching risperidone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia
- Interventions
- MK-5720, Placebo to MK-5720, MK-8189, Placebo to MK-8189
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more
- Conditions
- Schizophrenia
- Interventions
- Elpipodect, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Glendale, California • Marlton, New Jersey
- Conditions
- Alzheimer's Disease
- Interventions
- Elpipodect, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Santa Ana, California • Cutler Bay, Florida • Hallandale, Florida + 5 more
- Conditions
- Schizophrenia
- Interventions
- Elpipodect, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Rogers, Arkansas • Glendale, California • Long Beach, California + 3 more
- Conditions
- Bipolar I Disorder
- Interventions
- Elpipodect, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Atlanta, Georgia • Marlton, New Jersey
- Conditions
- Schizophrenia
- Interventions
- MK-8189, Placebo, Background AAP Therapy
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Schizophrenia
- Interventions
- Elpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 35
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more